Detail akcie Jazz Pharma online

Business Summary: Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Jazz Pharmaceuticals PLC revenues decreased less than 1% to $897.8M. Net loss increased from $14.6M to $92.5M. Revenues reflect Other Revenue segment increase of 34% to $4.8M, Europe segment increase of 17% to $83.6M, also reflect Xyrem segment decrease of 90% to $37.2M, Zepzelca segment decrease of 16% to $63M, United States segment decrease of 1% to $797.9M.